Skip to main content

Table 8 Trials of mTOR inhibitors in early-stage breast cancer: preoperative therapy

From: Antiangiogenic therapy for breast cancer

Reference

Phase

Number of patients

Treatment

Response

Macaskill et al. [85]

II

30

Everolimus (14 days prior to surgery)

Reduced cell proliferation

Baselga et al. [86]

II (randomised)

270

Everolimus + letrozole

RR 68%

   

Letrozole

59%

  1. mTOR, mammalian target of rapamycin; RR, response rate